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Abstract
Background: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). We explored the hypothesis
that asymptmatic hyperuricemia may be associated with new-onset CKD.
Methods: The participants were all male factory workers in Kanagawa, Japan (n = 1,285). All were over 40 years of
age and had undergone annual health examinations from 1990 to 2007. Individuals with a history of gouty attacks
were excluded from the study. A retrospective cohort study was conducted by following the estimated glomerular
filtration rate (eGFR) for each participant over a maximum period of 18 years. The endpoint was new-onset CKD
defined as eGFR < 60 mL/min/1.73 m
2. The associations between new-onset CKD and the presence of
hyperuricemia, low serum high-density lipoprotein cholesterol, hypertension, diabetes, and obesity were analyzed.
Results: The mean (± standard deviation) follow-up period was 95.2 (± 66.7) months, and new-onset CKD was
observed in 100 participants (7.8%) during this follow-up. Cox proportional hazards model revealed that the hazard
ratio of new-onset CKD due to hyperuricemia, low serum high-density lipoprotein cholesterol, hypertension and
obesity were 3.99 (95% confidence interval: 2.59-6.15), 1.69 (1.00-2.86), 2.00 (1.29-3.11) and 1.35 (0.87-2.10),
respectively. Concerning hyperuricemia, low serum high-density lipoprotein cholesterol, hypertension and obesity,
the log-rank tests showed P values of < 0.01, 0.01, < 0.01 and < 0.01, respectively.
Conclusion: The results of this study suggest that asymptomatic hyperuricemia is a predictive factor for new-onset
CKD for Japanese male workers.
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Background
End-stage renal disease (ESRD) poses a serious public
health problem as a result of the costs of treatments
such as dialysis and transplantation and harms the qual-
ity of life. Chronic kidney disease (CKD) precedes
ESRD, and the progression of CKD to ESRD can be pre-
ventable by appropriate treatment. Prevention of new-
onset CKD could effectively target ESRD. In 2002, the
Kidney Disease Outcomes Quality Initiative of the
National Kidney Foundation gave a definition and classi-
f i c a t i o ns y s t e mf o rC K D ,a n dC K Di sd e f i n e da se i t h e r
glomerular filtration rate (GFR) < 60 mL/min/1.73 m
2
or kidney damage lasting for at least 3 months [1]. The
estimated prevalences of CKD measured as GFR < 60
mL/min/1.73 m
2 are 8.1% in the United States [2] and
10.6% in Japan [3].
Previous studies have established hypertension [4-9]
and diabetes [10-13] as predictive factors for CKD. Dys-
lipidemia [6,14,15], obesity [7,16] and hyperuricemia
[17-20] have also been suggested to be predictive factors
for CKD. However, it is not clear if asymptomatic
hyperuricemia without gouty attacks is a risk factor for
CKD. The aim of this study was to determine the
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The participants were all male factory workers over 40
years of age who had undergone annual medical exami-
nations from 1990 to 2007. This retrospective cohort
study covered a maximum period of 18 years. To inves-
tigate the effects of asymptomatic hyperuricemia, 41
participants with a history of gouty attacks were
excluded from the analysis. Participants with only one
year of data, those lacking follow-up data, or those with
incomplete data were also excluded.
Disease Criteria
T h ep r e s e n c eo fh y p e r u r i c e m i a ,l o ws e r u mH D L - C ,
hypertension, diabetes, and obesity were based on data
from the participants’ first-year medical examinations.
Hyperuricemia was defined as a uric acid level of > 7.0
mg/dL. Low serum HDL-C was defined as HDL-C < 40
mg/dL. Hypertension was defined as a systolic blood
pressure of ≥ 140 mmHg or diastolic blood pressure of
≥ 90 mmHg. Diabetes was defined as a fasting blood
sugar level of ≥ 126 mg/dL. Obesity was defined as a
body mass index (BMI) of ≥ 25 kg/m
2.
Outcomes
The endpoint was new-onset CKD. New-onset CKD was
defined as the time point when estimated glomerular fil-
tration rate (eGFR) fellb e l o w6 0m L / m i n / 1 . 7 3m
2.T h e
eGFR was calculated based on the participant’sa g ea n d
serum creatinine (Cr) level, using the equation:
eGFR = 194 × Cr−1.094 × Age−0.287
determined by the Japanese Society of Nephrology
[21]. In this study, serum Cr was measured using the
Jaffe method from 1990 to 2002, and using the enzyme
method from 2003 to 2007. Because the equation for
estimating GFR used in this study is based on an
enzyme method, eGFR for the period from 1990 to 2002
was calculated using the serum Cr level after subtraction
of 0.2 mg/dL from the original serum Cr level [22]. Par-
ticipants were excluded from the analysis if their earliest
year’s eGFR was < 60 mL/min/1.73 m
2, if they had only
1 year’s worth of data or if they lacked follow-up data.
Statistical Analysis
The associations between new-onset CKD and the pre-
sence of hyperuricemia, low serum HDL-C, hypertension,
diabetes, and obesity were analyzed. The covariates
included age, hyperuricemia, low serum HDL-C, hyper-
tension, diabetes and obesity. The follow-up period (in
months) was the survival variable and new-onset CKD
was a state variable. To adjust for age and the presence of
disease as confounders, multivariate analysis was per-
formed using Cox regression analysis [23]. A hazard ratio
and 95% confidential interval (CI) were derived for each
covariate. The hazard ratio was determined to be signifi-
cant when the P value was < 0.05. In addition, Kaplan-
Meier curves and log-rank tests were used to estimate
the cumulative incidence of the covariates showing a sig-
nificant hazard ratio [24]. The Japanese version of SPSS
17.0 for Windows was used for the analyses [25].
Ethical Approval
This study was conducted with the approval of the
ethics committee of Kitasato University School of
Medicine.
Results
The study involved 1,285 participants with a mean (±
standard deviation [SD]) follow-up period of 95.2 (±
66.7) months. Of these participants, 100 (7.8%) developed
CKD during the follow-up period, and their mean (± SD)
follow-up period was 89.3 (± 62.0) months. The mean (±
SD) follow-up period for participants who did not
develop CKD was 95.7 (± 67.1) months. Table 1 shows
the baseline characteristics of the participants in terms of
age, levels of uric acid, HDL-C, systolic blood pressure,
diastolic blood pressure, fasting blood sugar, and BMI.
Hyperuricemia was detected in 166 participants (12.9%),
low serum HDL-C in 153 (11.9%), hypertension in 255
(19.8%), diabetes in 51 (4.0%), and obesity in 255 (19.8%).
Table 2 shows the prediction for new-onset CKD dur-
ing followed-up period. Of the participants with hyper-
uricemia at baseline, 32 (19.3%) developed CKD during
the follow-up period. The results of Cox regression ana-
lysis revealed that the hazard ratio for new-onset CKD
in the participants with hyperuricemia was 3.99 (95%
CI: 2.59-6.15), showing a significant association between
hyperuricemia and new-onset CKD. Likewise, the hazard
ratio for new-onset CKD was 1.69 (95% CI: 1.00-2.86) in
the participants with low serum HDL-C and 2.00 (95%
CI: 1.29-3.11) in those with hypertension, indicating sig-
nificant associations between new-onset CKD and these
variables. However, a hazard ratio of 0.56 (95% CI: 0.17-
1.77) indicated no significant association between new-
onset CKD and diabetes. The hazard ratio was 1.35
(95% CI: 0.87-2.10) in the participants with obesity, indi-
cating a weak association.
The cumulative incidence of CKD was analyzed by the
Kaplan-Meier method using the three variables (hyper-
uricemia, low serum HDL-C, and hypertension) showing
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showing a weak association with new-onset CKD in the
Cox proportional hazards model (Figure 1). Concerning
hyperuricemia, low serum HDL-C, hypertension and
obesity, the log-rank tests showed P values of < 0.01
(Figure 1-A), 0.01 (Figure 1-B), < 0.01 (Figure 1-C) and
< 0.01 (Figure 1-D), respectively.
Discussion
We investigated the associations between new-onset
CKD and asymptomatic hyperuricemia without gouty
attacks, low serum HDL-C, hypertension, diabetes and
obesity in Japanese male factory workers over 40 years
of age. The results showed a significantly higher inci-
dence of new-onset CKD in participants with asympto-
matic hyperuricemia. A significantly higher incidence of
new-onset CKD was also found in participants with low
serum HDL-C and hypertension. The incidence of new-
onset CKD tended to be higher, but not significantly, in
obese participants, whereas no significant increase in the
incidence of new-onset CKD was found in those with
diabetes.
Several studies have reported possible associations
between gouty attacks and renal function [26,27] and
have suggested an association between hyperuricemia
and CKD [17-20]. However, previous studies were not
noticed about asymptomatic hyperuricemia without
gouty attacks. Hyperuricemia in this study was defined
as a uric acid level above 7.0 mg/dL without gouty
attacks, and the hazard ratio for new-onset CKD in par-
ticipants with hyperuricemia was 3.99, indicating a sig-
nificant association. In addition, significant negative
correlations were found between the uric acid values at
the start of follow-up and the GFR values at the start of
follow-up, after follow-up for 5 years, and after follow-
up for 10 years (correlation coefficient: at the start of
follow-up, -0.21 p < 0.001; after 5 years, -0.20 p < 0.001;






41 - 45 273 21.2
46 - 50 276 21.5
51 - 55 220 17.1
≥ 56 83 6.5
Uric acid (mg/dL)
> 7.0 166 12.9
≤ 7.0 1,119 87.1
HDL-C (mg/dL)
< 40 153 11.9
≥ 40 1,132 88.1
Blood pressure (mmHg)
SBP ≥ 140 or DBP ≥ 90 255 19.8
SBP < 140 and DBP < 90 1,030 80.2
Fasting blood sugar (mg/dL)
≥ 126 51 4.0
< 126 1,234 96.0
Body mass index (kg/m
2)
≥ 25.0 255 19.8
< 25.0 1,030 80.2
HDL-C, high-density lipoprotein cholesterol
SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 2 Associations between predictors and new-onset CKD during a maximum period of 18 years follow-up




Hazard ratio 95% CI
Uric acid (mg/dL)
> 7.0 76.3 ± 63.3 32 19.3 3.99 2.59, 6.15
≤ 7.0 98.0 ± 66.8 68 6.1 1.00
HDL-C (mg/dL)
< 40 89.3 ± 61.5 18 11.8 1.69 1.00, 2.86
≥ 40 96.0 ± 67.4 82 7.2 1.00
Blood pressure (mmHg)
SBP ≥ 140 or DBP ≥ 90 83.5 ± 62.8 33 12.9 2.00 1.29, 3.11
SBP < 140 and DBP < 90 98.1 ± 67.4 67 6.5 1.00
Fasting blood sugar (mg/dL)
≥ 126 95.1 ± 66.0 3 5.9 0.56 0.17, 1.77
< 126 95.2 ± 66.8 97 7.9 1.00
Body mass index (kg/m
2)
≥ 25.0 93.2 ± 66.4 34 12.5 1.35 0.87, 2.10
< 25.0 95.7 ± 66.8 66 6.5 1.00
CKD, chronic kidney disease; SD, standard deviation; CI, confidence interval.
HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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uric acid level of 7.0 mg/dL is the diagnostic standard
for hyperuricemia in Japan [28]. Obermayr et al stated
in their report on 21,475 participants followed for 7
years, that the risk of new-onset CKD was increased by
a factor of 1.74 in those whose uric acid levels were 7.0-
8.9 mg/dL, and by a factor of 3.12 in those whose uric
acid levels were ≥ 9.0 mg/dL [17]. Iseki et al. conducted
a study in Japan and reported that the hazard ratio for
progression to ESRD was 5.77 in women with uric acid
levels of ≥ 6.0 mg/dL, showing a significant association,
whereas there was no significant association between
progression to ESRD and uric acid levels in men with
uric acid levels of ≥ 7.0 mg/dL [19]. A follow-up study
of patients with immunoglobulin A nephropathy for at
least 8 years reported that serum creatinine (Cr) levels
were significantly elevated in patients with hyperurice-
mia [20]. Hyperuricemia appeared to be affected by
other lifestyle-related diseases such as hypertension, dia-
betes and dyslipidemia, but a significant association
between hyperuricemia and new-onset CKD remained
even after adjusting for factors related to hypertension,
low serum HDL-C, obesity and diabetes. In this study,
the hazard ratio for asymptomatic hyperuricemia was
greater than those for other factors, including hyperten-
sion. Asymptomatic hyperuricemia was therefore sug-
gested not only to be a predictive factor for CKD, but
also to be a stronger predictor than established factors
such as hypertension and diabetes.
Dyslipidemia is thought to be a risk factor for new-
onset CKD. Previous studies detected associations
between CKD and decreased HDL-C [6,7,14,15,29],
increased total cholesterol [29,30], increased low-density
lipoprotein cholesterol [14,28,30], and increased trigly-
cerides [6,15]. However, several other studies found no
such significant associations, and further investigation
Time (months)
























































































( A )(  B )
( D ) ( C )
Log-rank P<0.01
Log-rank P<0.01 Log-rank P<0.01
Figure 1 Kaplan-Meier curves and Log-rank tests of CKD incidence. The Kaplan-Meier curves show the follow-up periods (in months) and
cumulative incidence rate of CKD. Solid lines represent cumulative incidence rates of CKD in participants with hyperuricemia (A), low serum
HDL-C (B), hypertension (C) and obesity (D) while dotted lines represent for the CKD rate in participants without these factors. Log-rank tests
were performed to determine differences in cumulative incidence rates. P values are shown in the figures. (A) UA > 7.0 mg/dL versus UA ≤ 7.0
mg/dL. (B) HDL-C < 40 mg/dL versus HDL-C ≥ 40 mg/dL. (C) (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) versus (SBP < 140 mmHg and DBP < 90
mmHg). (D) BMI ≥ 25.0 kg/m
2 versus BMI < 25.0 kg/m
2. CKD, chronic kidney disease; UA, uric acid; HDL-C, high-density lipoprotein cholesterol;
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
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pidemia and CKD. Low serum HDL-C in this study was
classified as HDL-C levels < 40 mg/dL, which is the
diagnostic standard for low HDL-C in the United States
(NCEP ATP III)[31] and in Japan (Japan Atherosclerosis
Society; Guidelines for Prevention of Atherosclerotic
Cardiovascular Diseases)[32]. When serum HDL-C was
low, the incidence of new-onset CKD increased signifi-
cantly (hazard ratio: 1.69), supporting an association
between dyslipidemia and CKD.
An association between hypertension and renal disease
has been established in a number of previous studies
[4-9]. Increases in blood pressure have also been reported
to be associated with increases in the incidence of ESRD
[8,33,34], and progression of CKD can be prevented by
antihypertensive treatment [5,8,9]. In this study, hyper-
tension was defined as a systolic blood pressure of ≥ 140
mmHg or diastolic blood pressure of ≥ 90 mmHg. This is
the standard classification for stage I hypertension in the
United States (JNC7)[35] and mild hypertension in Japan
(JSH2009)[36] and is used as the diagnostic standard for
hypertension. The hazard ratio for new-onset CKD in
our study was 2.00, showing a significant association with
hypertension. These results are consistent with those
from several previous studies that also found an associa-
tion between hypertension and CKD.
Diabetes is an established predictor of renal disease
[10-13]. However, we found no significant association
between diabetes and new-onset CKD. GFR decreases
with the duration of diabetes, but it has been suggested
that glomerular hyperfiltration occurs during the early
stage of diabetes, leading to a temporary increase in
GFR [37]. The mean (± SD) follow-up period was 95.1
(± 66.0) months in our participants with diabetes, but it
is possible that the GFR was increased or not markedly
decreased in some participants who were still in the
hyperfiltration phase. Thus, it is necessary to determine
the presence of new-onset CKD employing urinary albu-
min measurement in participants with diabetic nephro-
pathy during the early stage. Diabetes reportedly did not
significantly affect the progression of CKD in Japanese
participants; significant reductions in GFR might not
have been observed because of hyperfiltration, as
observed in this study [6].
Obesity has been suggested to be a risk factor for
ESRD [7,16]. Kramer et al. reported that the risk of
new-onset CKD was increased by a factor of 1.21 in par-
ticipants whose BMI was 25.0-29.9 kg/m
2 and by a fac-
tor of 1.40 in those whose BMI was ≥ 30 kg/m
2[38].
However, a study conducted in Japanese participants
found that a BMI of ≥ 25 kg/m
2 in male participants
had no effect on the progression of CKD to stage III or
more severe disease [6]. In our study, a BMI of 25 kg/
m
2 was used as the standard for defining obesity,
according to the criteria for obesity in Japan (Guidelines
for the Treatment of Obesity, 2006)[39]. The hazard
ratio for new-onset CKD in participants with obesity
was 1.35, showing no significant association; however, a
weak association was observed, since the 95% CI was
0.87-2.10. Further studies with longer follow-up periods
in more participants are needed to clarify the association
between obesity and new-onset CKD.
In this study, new-onset CKD was defined as GFR < 60
mL/min/1.73 m
2. It is therefore important to clarify the
methods used for estimating the GFR; GFR-estimating
equations for Japanese devised by the Japanese Society of
Nephrology in March, 2008 [21]. Imai et al. previously
reported a different equation for estimating GFR in Japa-
nese participants [40], but it has been suggested that this
might underestimate GFR values. The equation used in
t h ec u r r e n ts t u d yw a sar e v i s e dv e r s i o no ft h ep r e v i o u s
equation, and might produce more accurate estimates of
GFR in the Japanese population. According to the diag-
nostic criteria for CKD, abnormal urinalysis results, such
as proteinuria, and abnormal findings on echography,
can also be used to diagnose CKD. However, in line with
many previous studies, the current study defined CKD as
GFR < 60 mL/min/1.73 m
2.
Hyperuricemia, low serum HDL-C, hypertension, dia-
betes, and obesity were defined in this study based on
the first year’s data for each participant. Treatment for
any of these diseases was not taken into account, except
for the exclusion of any individuals with a history of
gouty attacks. It is therefore possible that some of the
participants who were classified as a uric acid level of ≤
7.0 mg/dL were actually receiving treatment. In this
case, compared with strictly extracting participants who
have treatment of hyperuricemia, the power of statisti-
cally significance of the association between hyperurice-
mia and CKD could be low. However, hyperuricemia
could be a predictive factor for new-onset CKD in this
study, as suggested by the significant association
between hyperuricemia and new-onset CKD.
Conclusions
The results of this study suggest that asymptomatic
hyperuricemia without gouty attacks is a predictive fac-
tor for new-onset CKD. Therefore, the appropriate
treatment might reduce the number of patients of CKD.
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